Literature DB >> 18037942

Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation.

R L Haspel1, G Kao, B Y Yeap, C Cutler, R J Soiffer, E P Alyea, V T Ho, J Koreth, B R Dey, S L McAfee, E C Attar, T Spitzer, J H Antin, K K Ballen.   

Abstract

Double cord blood transplantation (DCBT) may overcome the slow hematopoietic recovery and engraftment failure associated with infusion of a single cord blood unit. In DCBT, only one unit typically contributes to long-term hematopoiesis, but little is known about factors affecting cord predominance. As results from a phase I trial suggested that order of infusion may affect cord predominance, we analyzed the effect of preinfusion variables on chimerism patterns of 38 patients enrolled in the initial study and a subsequent phase II trial. All patients were treated with a reduced-intensity conditioning (RIC) regimen of fludarabine, melphalan and thymoglobulin followed by DCBT. By day 100, 66% of patients had hematopoiesis derived from a single cord blood unit. Higher post-thaw total nucleated cell and CD34+ cell dose were associated with cord predominance and in 68% of patients (P=0.03); the predominant cord blood unit was infused first. Only the post-thaw CD34+ cell dose of the predominant unit predicted time to both neutrophil and platelet engraftment. Although based on a small number of patients, our results identify parameters that may affect cord predominance and engraftment in the setting of DCBT following RIC and suggest possible strategies for selecting infusion order for cord blood units.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037942      PMCID: PMC2947748          DOI: 10.1038/sj.bmt.1705933

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  18 in total

1.  Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches.

Authors:  S K Nilsson; H M Johnston; J A Coverdale
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  The relationship between the spleen colony-forming cell and the haemopoietic stem cell.

Authors:  R Schofield
Journal:  Blood Cells       Date:  1978

3.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

4.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.

Authors:  Mary J Laughlin; Mary Eapen; Pablo Rubinstein; John E Wagner; Mei-Jei Zhang; Richard E Champlin; Cladd Stevens; Juliet N Barker; Robert P Gale; Hillard M Lazarus; David I Marks; Jon J van Rood; Andromachi Scaradavou; Mary M Horowitz
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

5.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.

Authors:  P Rubinstein; L Dobrila; R E Rosenfield; J W Adamson; G Migliaccio; A R Migliaccio; P E Taylor; C E Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 6.  Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation.

Authors:  C Cutler; J H Antin
Journal:  Bone Marrow Transplant       Date:  2004-09       Impact factor: 5.483

7.  Identification of the haematopoietic stem cell niche and control of the niche size.

Authors:  Jiwang Zhang; Chao Niu; Ling Ye; Haiyang Huang; Xi He; Wei-Gang Tong; Jason Ross; Jeff Haug; Teri Johnson; Jian Q Feng; Stephen Harris; Leanne M Wiedemann; Yuji Mishina; Linheng Li
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

8.  Osteoblastic cells regulate the haematopoietic stem cell niche.

Authors:  L M Calvi; G B Adams; K W Weibrecht; J M Weber; D P Olson; M C Knight; R P Martin; E Schipani; P Divieti; F R Bringhurst; L A Milner; H M Kronenberg; D T Scadden
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

9.  Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.

Authors:  Satoshi Takahashi; Tohru Iseki; Jun Ooi; Akira Tomonari; Kashiya Takasugi; Yoko Shimohakamada; Toshiki Yamada; Kaoru Uchimaru; Arinobu Tojo; Naoki Shirafuji; Hideki Kodo; Kenzaburo Tani; Tsuneo Takahashi; Takuhiro Yamaguchi; Shigetaka Asano
Journal:  Blood       Date:  2004-07-27       Impact factor: 22.113

10.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

View more
  19 in total

1.  Donor-derived second hematologic malignancies after cord blood transplantation.

Authors:  Karen K Ballen; Corey Cutler; Beow Y Yeap; Steven L McAfee; Bimalangshu R Dey; Eyal C Attar; Yi-Bin Chen; Richard L Haspel; Deborah Liney; John Koreth; Vincent Ho; Edwin P Alyea; Robert J Soiffer; Thomas R Spitzer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-21       Impact factor: 5.742

2.  Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.

Authors:  Corey Cutler; Haesook T Kim; Lixian Sun; Doreen Sese; Brett Glotzbecker; Philippe Armand; John Koreth; Vincent Ho; Edwin Alyea; Karen Ballen; Jerome Ritz; Robert J Soiffer; Edgar Milford; Joseph H Antin
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

3.  Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation.

Authors:  Richard Mitchell; John E Wagner; Claudio Brunstein; Qing Cao; David H McKenna; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-15       Impact factor: 5.742

Review 4.  Strategies to enhance umbilical cord blood stem cell engraftment in adult patients.

Authors:  Colleen Delaney; Mariusz Z Ratajczak; Mary J Laughlin
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

5.  Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.

Authors:  Sharon Avery; Weiji Shi; Marissa Lubin; Anne Marie Gonzales; Glenn Heller; Hugo Castro-Malaspina; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

6.  Overcoming the barriers to umbilical cord blood transplantation.

Authors:  Susan Staba Kelly; Simrit Parmar; Marcos De Lima; Simon Robinson; Elizabeth Shpall
Journal:  Cytotherapy       Date:  2010-04       Impact factor: 5.414

Review 7.  An overview of the progress on double umbilical cord blood transplantation.

Authors:  Anastasia Sideri; Nikolaos Neokleous; Philippe Brunet De La Grange; Bernadette Guerton; Marie-Caroline Le Bousse Kerdilles; Georges Uzan; Corina Peste-Tsilimidos; Eliane Gluckman
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

8.  Stable mixed donor-donor chimerism after double cord blood transplantation.

Authors:  Sofia Berglund; Mantas Okas; Jens Gertow; Michael Uhlin; Jonas Mattsson
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

9.  Correlation of infused CD3+CD8+ cells with single-donor dominance after double-unit cord blood transplantation.

Authors:  Filippo Milano; Shelly Heimfeld; Ted Gooley; Jack Jinneman; Ian Nicoud; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-16       Impact factor: 5.742

10.  The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML.

Authors:  P Hagen; J E Wagner; T E DeFor; M Dolan; M Arora; E Warlick; D Weisdorf; C G Brunstein
Journal:  Bone Marrow Transplant       Date:  2014-09-22       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.